Regulatory, legal and policy aspects

Workpackage #8

Regulatory, legal and policy aspects

iCARE4CVD’s vision to pave the way to better care for individuals with
CVD could not be realised without careful insight into the regulatory, legal,
reimbursement, and policy landscape relevant to CVD. By defining a
roadmap, framework, and a strategy for biomarker and medical AI
developments that is safe, ethical, and successful, WP8 will aim to
facilitate a successful adaption and implementation of iCARE4CVD’s
medical tools.

Meet our team

Scientific Institute for Health Economics and Health Systems Research

Ines Weinhold

Manager
Read more

TNO

Gabriela Bodea , MA

Dutch Organisation for Applied Research
Read more

Decentriq

Maria Fernanda Scoz Luz

Business Development Manager
Read more

Novo Nordisk

G. Kees Hovingh

Senior Medical Officer
Read more

TNO

Willem van den Brink, PhD

Netherlands Organisation for Applied Scientific Research
Read more

Scientific Institute for Health Economics and Health Systems Research

Franziska Sende

Research associate
Read more
Get updated

Our related news

Read more

10 September, 2024

New publication: Evaluating digital care for heart failure using patient experience measures – A scoping review

Heart failure (heart failure) is a serious condition that affects many people..

Read more

3 September, 2024

Our second iCARE4CVD consortium meeting comes to a close

The iCARE4CVD consortium has successfully concluded its latest meeting, bringing together our..

Read more

5 June, 2024

iCARE4CVD launches federated database

The iHi-funded research project, iCARE4CVD, is a collaborative effort to personalize prevention..

Read more

Subscribe to our newsletter

Subscribe to our newsletter to stay up to date with all the most recent information about iCARE4CVD.

Funding acknowledgment

Funding aknowledgement This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) and JDRF International under grant agreement No 101112022. The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Vaccines Europe, EuropaBio and MedTech Europe.

Disclaimer

Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

Quick Links